Clinical Trial Update: BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update of BXCL701 in combination with pembrolizumab for metastatic pancreatic ductal adenocarcinoma, with the study currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BXCL701
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Georgetown University | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING